{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T10:27:30Z","timestamp":1757586450698},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"S1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s40120-017-0071-y","type":"journal-article","created":{"date-parts":[[2017,7,21]],"date-time":"2017-07-21T13:10:19Z","timestamp":1500642619000},"page":"69-81","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["A Review of Biomarkers for Alzheimer\u2019s Disease in Down Syndrome"],"prefix":"10.1007","volume":"6","author":[{"given":"Ni-Chung","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin-Hsiu","family":"Chien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wuh-Liang","family":"Hwu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,21]]},"reference":[{"issue":"3","key":"71_CR1","first-page":"158","volume":"32","author":"SJ Lin","year":"1991","unstructured":"Lin SJ, Hu SC, Sheu SF, Ho JW, Chiou PC, Chao MC, et al. Anthropometric study on Down syndrome in Taiwan. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1991;32(3):158\u201364.","journal-title":"Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi."},{"key":"71_CR2","first-page":"1301","volume":"54","author":"CDC","year":"2006","unstructured":"CDC. Improved national prevalence estimates for 18 selected major birth defects\u2014United States, 1999\u20132001. MMWR Morb Mortal Wkly Rep. 2006;54:1301\u20135.","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"71_CR3","unstructured":"AAP issues guidelines on health supervision for children with Down syndrome. Am Fam Phys. 1994;50(3):695\u20137."},{"issue":"4","key":"71_CR4","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1469-8749.2004.tb00483.x","volume":"46","author":"AH Bittles","year":"2004","unstructured":"Bittles AH, Glasson EJ. Clinical, social, and ethical implications of changing life expectancy in Down syndrome. Dev Med Child Neurol. 2004;46(4):282\u20136.","journal-title":"Dev Med Child Neurol."},{"issue":"8","key":"71_CR5","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/bies.10138","volume":"24","author":"S Arbuzova","year":"2002","unstructured":"Arbuzova S, Hutchin T, Cuckle H. Mitochondrial dysfunction and Down\u2019s syndrome. BioEssays. 2002;24(8):681\u20134.","journal-title":"BioEssays."},{"issue":"14","key":"71_CR6","doi-asserted-by":"crossref","first-page":"dn1","DOI":"10.1126\/sageke.2005.14.dn1","volume":"2005","author":"DA Devenny","year":"2005","unstructured":"Devenny DA, Wegiel J, Schupf N, Jenkins E, Zigman W, Krinsky-McHale SJ, et al. Dementia of the Alzheimer\u2019s type and accelerated aging in Down syndrome. Sci Aging Knowl Environ. 2005;2005(14):dn1.","journal-title":"Sci Aging Knowl Environ."},{"key":"71_CR7","unstructured":"Online Mendelian Inheritance in Man [Internet]. Johns Hopkins University. 2006. Available from: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/dispomim.cgi?id=190685 . Accessed 25 Feb 2006"},{"key":"71_CR8","first-page":"157","volume-title":"Thompson & Thompson genetics in medicine","author":"RL Willard","year":"2001","unstructured":"Willard RL. Thompson & Thompson genetics in medicine. 6th ed. Philadelphia: Saunders; 2001. p. 157\u201379.","edition":"6"},{"key":"71_CR9","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.neurobiolaging.2006.03.008","volume":"28","author":"M Zana","year":"2006","unstructured":"Zana M, Janka Z, Kalman J. Oxidative stress: a bridge between Down\u2019s syndrome and Alzheimer\u2019s disease. Neurobiol Aging. 2006;28:648\u201376.","journal-title":"Neurobiol Aging."},{"key":"71_CR10","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/BF02876635","volume":"122","author":"F Struwe","year":"1929","unstructured":"Struwe F. Histopathologische Untersuchungen \u00fcber Entstehung und Wesen der senilen Plaques. Z Gesamte Neurol Psychiatr. 1929;122:291\u2013307.","journal-title":"Z Gesamte Neurol Psychiatr."},{"issue":"22","key":"71_CR11","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1056\/NEJM198906013202203","volume":"320","author":"B Rumble","year":"1989","unstructured":"Rumble B, Retallack R, Hilbich C, Simms G, Multhaup G, Martins R, et al. Amyloid A4 protein and its precursor in Down\u2019s syndrome and Alzheimer\u2019s disease. N Engl J Med. 1989;320(22):1446\u201352.","journal-title":"N Engl J Med."},{"issue":"1","key":"71_CR12","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2174\/1567205012666151020114607","volume":"13","author":"E Head","year":"2016","unstructured":"Head E, Lott IT, Wilcock DM, Lemere CA. Aging in Down syndrome and the development of Alzheimer\u2019s disease neuropathology. Curr Alzheimer Res. 2016;13(1):18\u201329.","journal-title":"Curr Alzheimer Res."},{"issue":"1","key":"71_CR13","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1006\/nbdi.1996.0003","volume":"3","author":"CA Lemere","year":"1996","unstructured":"Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis. 1996;3(1):16\u201332.","journal-title":"Neurobiol Dis."},{"issue":"4","key":"71_CR14","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00401-011-0864-5","volume":"122","author":"QS Xue","year":"2011","unstructured":"Xue QS, Streit WJ. Microglial pathology in Down syndrome. Acta Neuropathol. 2011;122(4):455\u201366.","journal-title":"Acta Neuropathol."},{"issue":"8","key":"71_CR15","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.arcmed.2012.10.012","volume":"43","author":"AM Cardenas","year":"2012","unstructured":"Cardenas AM, Ardiles AO, Barraza N, Baez-Matus X, Caviedes P. Role of tau protein in neuronal damage in Alzheimer\u2019s disease and Down syndrome. Arch Med Res. 2012;43(8):645\u201354.","journal-title":"Arch Med Res."},{"issue":"9","key":"71_CR16","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nrn3983","volume":"16","author":"FK Wiseman","year":"2015","unstructured":"Wiseman FK, Al-Janabi T, Hardy J, Karmiloff-Smith A, Nizetic D, Tybulewicz VL, et al. A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat Rev Neurosci. 2015;16(9):564\u201374.","journal-title":"Nat Rev Neurosci."},{"issue":"6","key":"71_CR17","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jalz.2014.10.007","volume":"11","author":"D Hartley","year":"2015","unstructured":"Hartley D, Blumenthal T, Carrillo M, DiPaolo G, Esralew L, Gardiner K, et al. Down syndrome and Alzheimer\u2019s disease: common pathways, common goals. Alzheimers Dement. 2015;11(6):700\u20139.","journal-title":"Alzheimers Dement."},{"issue":"5","key":"71_CR18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0888-7543(03)00035-1","volume":"81","author":"R Mao","year":"2003","unstructured":"Mao R, Zielke CL, Zielke HR, Pevsner J. Global up-regulation of chromosome 21 gene expression in the developing Down syndrome brain. Genomics. 2003;81(5):457\u201367.","journal-title":"Genomics."},{"issue":"3","key":"71_CR19","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/ana.410430316","volume":"43","author":"VP Prasher","year":"1998","unstructured":"Prasher VP, Farrer MJ, Kessling AM, Fisher EM, West RJ, Barber PC, et al. Molecular mapping of Alzheimer-type dementia in Down\u2019s syndrome. Ann Neurol. 1998;43(3):380\u20133.","journal-title":"Ann Neurol."},{"issue":"5","key":"71_CR20","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0896-6273(02)00604-9","volume":"33","author":"J Busciglio","year":"2002","unstructured":"Busciglio J, Pelsman A, Wong C, Pigino G, Yuan M, Mori H, et al. Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down\u2019s syndrome. Neuron. 2002;33(5):677\u201388.","journal-title":"Neuron."},{"issue":"23","key":"71_CR21","doi-asserted-by":"crossref","first-page":"6951","DOI":"10.1021\/bi000169p","volume":"39","author":"H Misonou","year":"2000","unstructured":"Misonou H, Morishima-Kawashima M, Ihara Y. Oxidative stress induces intracellular accumulation of amyloid beta-protein (Abeta) in human neuroblastoma cells. Biochemistry. 2000;39(23):6951\u20139.","journal-title":"Biochemistry."},{"issue":"2","key":"71_CR22","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1006\/bbrc.2000.2164","volume":"268","author":"D Paola","year":"2000","unstructured":"Paola D, Domenicotti C, Nitti M, Vitali A, Borghi R, Cottalasso D, et al. Oxidative stress induces increase in intracellular amyloid beta-protein production and selective activation of betaI and betaII PKCs in NT2 cells. Biochem Biophys Res Commun. 2000;268(2):642\u20136.","journal-title":"Biochem Biophys Res Commun."},{"key":"71_CR23","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991;82:239\u201359.","journal-title":"Acta Neuropathol."},{"issue":"10","key":"71_CR24","doi-asserted-by":"crossref","first-page":"2441 e1\u20135","DOI":"10.1016\/j.neurobiolaging.2013.03.018","volume":"34","author":"EL Jones","year":"2013","unstructured":"Jones EL, Mok K, Hanney M, Harold D, Sims R, Williams J, et al. Evidence that PICALM affects age at onset of Alzheimer\u2019s dementia in Down syndrome. Neurobiol Aging. 2013;34(10):2441 e1\u20135.","journal-title":"Neurobiol Aging."},{"issue":"2","key":"71_CR25","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1042\/BJ20061451","volume":"404","author":"V Dorval","year":"2007","unstructured":"Dorval V, Mazzella MJ, Mathews PM, Hay RT, Fraser PE. Modulation of Abeta generation by small ubiquitin-like modifiers does not require conjugation to target proteins. Biochem J. 2007;404(2):309\u201316.","journal-title":"Biochem J."},{"issue":"6","key":"71_CR26","first-page":"1513 e1\u20135","volume":"35","author":"KY Mok","year":"2014","unstructured":"Mok KY, Jones EL, Hanney M, Harold D, Sims R, Williams J, et al. Polymorphisms in BACE2 may affect the age of onset Alzheimer\u2019s dementia in Down syndrome. Neurobiol Aging. 2014;35(6):1513 e1\u20135.","journal-title":"Neurobiol Aging."},{"issue":"2","key":"71_CR27","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.neulet.2010.10.010","volume":"487","author":"A Patel","year":"2011","unstructured":"Patel A, Rees SD, Kelly MA, Bain SC, Barnett AH, Thalitaya D, et al. Association of variants within APOE, SORL1, RUNX1, BACE1 and ALDH18A1 with dementia in Alzheimer\u2019s disease in subjects with Down syndrome. Neurosci Lett. 2011;487(2):144\u20138.","journal-title":"Neurosci Lett."},{"issue":"5","key":"71_CR28","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1471-4159.2007.05075.x","volume":"104","author":"SR Ryoo","year":"2008","unstructured":"Ryoo SR, Cho HJ, Lee HW, Jeong HK, Radnaabazar C, Kim YS, et al. Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer\u2019s disease. J Neurochem. 2008;104(5):1333\u201344.","journal-title":"J Neurochem."},{"issue":"2","key":"71_CR29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.neulet.2007.08.042","volume":"425","author":"JH Lee","year":"2007","unstructured":"Lee JH, Chulikavit M, Pang D, Zigman WB, Silverman W, Schupf N. Association between genetic variants in sortilin-related receptor 1 (SORL1) and Alzheimer\u2019s disease in adults with Down syndrome. Neurosci Lett. 2007;425(2):105\u20139.","journal-title":"Neurosci Lett."},{"issue":"2","key":"71_CR30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0167-4781(03)00121-0","volume":"1628","author":"EW Wolvetang","year":"2003","unstructured":"Wolvetang EW, Bradfield OM, Tymms M, Zavarsek S, Hatzistavrou T, Kola I, et al. The chromosome 21 transcription factor ETS2 transactivates the beta-APP promoter: implications for Down syndrome. Biochim Biophys Acta. 2003;1628(2):105\u201310.","journal-title":"Biochim Biophys Acta."},{"issue":"4","key":"71_CR31","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.3233\/JAD-140984","volume":"43","author":"K Henriksen","year":"2015","unstructured":"Henriksen K, Byrjalsen I, Christiansen C, Karsdal MA. Relationship between serum levels of tau fragments and clinical progression of Alzheimer\u2019s disease. J Alzheimer\u2019s Dis. 2015;43(4):1331\u201341.","journal-title":"J Alzheimer\u2019s Dis."},{"issue":"8","key":"71_CR32","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1097\/00001756-199705260-00009","volume":"8","author":"GE Alexander","year":"1997","unstructured":"Alexander GE, Saunders AM, Szczepanik J, Strassburger TL, Pietrini P, Dani A, et al. Relation of age and apolipoprotein E to cognitive function in Down syndrome adults. NeuroReport. 1997;8(8):1835\u201340.","journal-title":"NeuroReport."},{"issue":"3","key":"71_CR33","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3233\/JAD-2011-110860","volume":"28","author":"C Chace","year":"2012","unstructured":"Chace C, Pang D, Weng C, Temkin A, Lax S, Silverman W, et al. Variants in CYP17 and CYP19 cytochrome P450 genes are associated with onset of Alzheimer\u2019s disease in women with down syndrome. J Alzheimer\u2019s Dis. 2012;28(3):601\u201312.","journal-title":"J Alzheimer\u2019s Dis."},{"issue":"11","key":"71_CR34","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/gps.2039","volume":"23","author":"VP Prasher","year":"2008","unstructured":"Prasher VP, Sajith SG, Rees SD, Patel A, Tewari S, Schupf N, et al. Significant effect of APOE epsilon 4 genotype on the risk of dementia in Alzheimer\u2019s disease and mortality in persons with Down syndrome. Int J Geriatr Psychiatry. 2008;23(11):1134\u201340.","journal-title":"Int J Geriatr Psychiatry."},{"key":"71_CR35","volume-title":"Risk factors for dementia in Down syndrome","author":"LY Huang","year":"2016","unstructured":"Huang LY. Risk factors for dementia in Down syndrome. Taiwan: National Taiwan University; 2016."},{"issue":"4","key":"71_CR36","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000334522","volume":"32","author":"Q Zhao","year":"2011","unstructured":"Zhao Q, Lee JH, Pang D, Temkin A, Park N, Janicki SC, et al. Estrogen receptor-Beta variants are associated with increased risk of Alzheimer\u2019s disease in women with down syndrome. Dement Geriatr Cogn Disord. 2011;32(4):241\u20139.","journal-title":"Dement Geriatr Cogn Disord."},{"key":"71_CR37","doi-asserted-by":"crossref","first-page":"170276","DOI":"10.1155\/2012\/170276","volume":"2012","author":"DM Wilcock","year":"2012","unstructured":"Wilcock DM. Neuroinflammation in the aging down syndrome brain; lessons from Alzheimer\u2019s disease. Curr Gerontol Geriatr Res. 2012;2012:170276.","journal-title":"Curr Gerontol Geriatr Res."},{"issue":"9","key":"71_CR38","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1016\/j.neurobiolaging.2015.05.016","volume":"36","author":"DM Wilcock","year":"2015","unstructured":"Wilcock DM, Hurban J, Helman AM, Sudduth TL, McCarty KL, Beckett TL, et al. Down syndrome individuals with Alzheimer\u2019s disease have a distinct neuroinflammatory phenotype compared to sporadic Alzheimer\u2019s disease. Neurobiol Aging. 2015;36(9):2468\u201374.","journal-title":"Neurobiol Aging."},{"issue":"Database issue","key":"71_CR39","doi-asserted-by":"crossref","first-page":"D109","DOI":"10.1093\/nar\/gkh023","volume":"32","author":"S Griffiths-Jones","year":"2004","unstructured":"Griffiths-Jones S. The microRNA Registry. Nucl Acids Res. 2004;32(Database issue):D109\u201311.","journal-title":"Nucl Acids Res."},{"key":"71_CR40","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1007\/s12035-015-9201-7","volume":"53","author":"JF Codocedo","year":"2016","unstructured":"Codocedo JF, Rios JA, Godoy JA, Inestrosa NC. Are microRNAs the molecular link between metabolic syndrome and Alzheimer\u2019s disease? Mol Neurobiol. 2016;53:2320\u201338.","journal-title":"Mol Neurobiol."},{"issue":"1","key":"71_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JAD-150451","volume":"49","author":"Y Pan","year":"2015","unstructured":"Pan Y, Liu R, Terpstra E, Wang Y, Qiao F, Wang J, et al. Dysregulation and diagnostic potential of microRNA in Alzheimer\u2019s disease. J Alzheimer\u2019s Dis. 2015;49(1):1\u201312.","journal-title":"J Alzheimer\u2019s Dis."},{"key":"71_CR42","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cortex.2015.07.032","volume":"73","author":"AD Dekker","year":"2015","unstructured":"Dekker AD, Strydom A, Coppus AM, Nizetic D, Vermeiren Y, Naude PJ, et al. Behavioural and psychological symptoms of dementia in Down syndrome: early indicators of clinical Alzheimer\u2019s disease? Cortex. 2015;73:36\u201361.","journal-title":"Cortex."},{"issue":"1","key":"71_CR43","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2174\/1567205012666150921095724","volume":"13","author":"M Sabbagh","year":"2016","unstructured":"Sabbagh M, Edgin J. Clinical assessment of cognitive decline in adults with Down syndrome. Curr Alzheimer Res. 2016;13(1):30\u20134.","journal-title":"Curr Alzheimer Res."},{"issue":"Pt 1","key":"71_CR44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1348\/014466507X230967","volume":"47","author":"SL Ball","year":"2008","unstructured":"Ball SL, Holland AJ, Treppner P, Watson PC, Huppert FA. Executive dysfunction and its association with personality and behaviour changes in the development of Alzheimer\u2019s disease in adults with Down syndrome and mild to moderate learning disabilities. Br J Clin Psychol. 2008;47(Pt 1):1\u201329.","journal-title":"Br J Clin Psychol."},{"issue":"4","key":"71_CR45","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ridd.2003.12.002","volume":"25","author":"V Prasher","year":"2004","unstructured":"Prasher V, Farooq A, Holder R. The Adaptive Behaviour Dementia Questionnaire (ABDQ): screening questionnaire for dementia in Alzheimer\u2019s disease in adults with Down syndrome. Res Dev Disabil. 2004;25(4):385\u201397.","journal-title":"Res Dev Disabil."},{"key":"71_CR46","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/jir.12200","volume":"59","author":"DM Walsh","year":"2015","unstructured":"Walsh DM, Doran E, Silverman W, Tournay A, Movsesyan N, Lott IT. Rapid assessment of cognitive function in down syndrome across intellectual level and dementia status. J Intellect Disabil Res. 2015;59:1071\u20139.","journal-title":"J Intellect Disabil Res."},{"key":"71_CR47","volume-title":"Dementia scale for Down syndrome: manual","author":"A Gedye","year":"1995","unstructured":"Gedye A. Dementia scale for Down syndrome: manual. Vancouver: Gedye Research and Consulting; 1995."},{"issue":"Pt 4","key":"71_CR48","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2788.1996.tb00642.x","volume":"40","author":"HM Evenhuis","year":"1996","unstructured":"Evenhuis HM. Further evaluation of the Dementia Questionnaire for Persons with Mental Retardation (DMR). J Intellect Disabil Res. 1996;40(Pt 4):369\u201373.","journal-title":"J Intellect Disabil Res."},{"key":"71_CR49","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1192\/bjp.bp.106.024984","volume":"190","author":"S Deb","year":"2007","unstructured":"Deb S, Hare M, Prior L, Bhaumik S. Dementia screening questionnaire for individuals with intellectual disabilities. Br J Psychiatry J Mental Sci. 2007;190:440\u20134.","journal-title":"Br J Psychiatry J Mental Sci."},{"key":"71_CR50","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.nicl.2013.03.014","volume":"2","author":"R Vandenberghe","year":"2013","unstructured":"Vandenberghe R, Adamczuk K, Dupont P, Laere KV, Chetelat G. Amyloid PET in clinical practice: its place in the multidimensional space of Alzheimer\u2019s disease. Neuroimage Clin. 2013;2:497\u2013511.","journal-title":"Neuroimage Clin."},{"issue":"11","key":"71_CR51","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1001\/archneurol.2011.535","volume":"68","author":"MN Sabbagh","year":"2011","unstructured":"Sabbagh MN, Fleisher A, Chen K, Rogers J, Berk C, Reiman E, et al. Positron emission tomography and neuropathologic estimates of fibrillar amyloid-beta in a patient with Down syndrome and Alzheimer disease. Arch Neurol. 2011;68(11):1461\u20136.","journal-title":"Arch Neurol."},{"issue":"5","key":"71_CR52","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1212\/WNL.0000000000001212","volume":"84","author":"D Jennings","year":"2015","unstructured":"Jennings D, Seibyl J, Sabbagh M, Lai F, Hopkins W, Bullich S, et al. Age dependence of brain beta-amyloid deposition in Down syndrome: an [18F]florbetaben PET study. Neurology. 2015;84(5):500\u20137.","journal-title":"Neurology."},{"issue":"6","key":"71_CR53","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jalz.2011.09.229","volume":"8","author":"BL Handen","year":"2012","unstructured":"Handen BL, Cohen AD, Channamalappa U, Bulova P, Cannon SA, Cohen WI, et al. Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B. Alzheimers Dement. 2012;8(6):496\u2013501.","journal-title":"Alzheimers Dement."},{"issue":"5","key":"71_CR54","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jalz.2015.07.490","volume":"12","author":"T Annus","year":"2016","unstructured":"Annus T, Wilson LR, Hong YT, Acosta-Cabronero J, Fryer TD, Cardenas-Blanco A, et al. The pattern of amyloid accumulation in the brains of adults with Down syndrome. Alzheimers Dement. 2016;12(5):538\u201345.","journal-title":"Alzheimers Dement."},{"issue":"7","key":"71_CR55","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1002\/hbm.22390","volume":"35","author":"MJ Chiu","year":"2014","unstructured":"Chiu MJ, Chen YF, Chen TF, Yang SY, Yang FP, Tseng TW, et al. Plasma tau as a window to the brain-negative associations with brain volume and memory function in mild cognitive impairment and early Alzheimer\u2019s disease. Hum Brain Mapp. 2014;35(7):3132\u201342.","journal-title":"Hum Brain Mapp."},{"issue":"18","key":"71_CR56","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1097\/00001756-199611250-00026","volume":"7","author":"A Dani","year":"1996","unstructured":"Dani A, Pietrini P, Furey ML, McIntosh AR, Grady CL, Horwitz B, et al. Brain cognition and metabolism in Down syndrome adults in association with development of dementia. NeuroReport. 1996;7(18):2933\u20136.","journal-title":"NeuroReport."},{"key":"71_CR57","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3389\/fnbeh.2015.00239","volume":"9","author":"MS Rafii","year":"2015","unstructured":"Rafii MS, Wishnek H, Brewer JB, Donohue MC, Ness S, Mobley WC, et al. The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer\u2019s disease biomarkers in down syndrome. Front Behav Neurosci. 2015;9:239.","journal-title":"Front Behav Neurosci."},{"issue":"7","key":"71_CR58","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1212\/WNL.56.7.979","volume":"56","author":"T Tapiola","year":"2001","unstructured":"Tapiola T, Soininen H, Pirttila T. CSF tau and Abeta42 levels in patients with Down\u2019s syndrome. Neurology. 2001;56(7):979\u201380.","journal-title":"Neurology."},{"issue":"4","key":"71_CR59","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3143\/geriatrics.35.273","volume":"35","author":"A Tamaoka","year":"1998","unstructured":"Tamaoka A. Characterization of amyloid beta protein species in the plasma, cerebrospinal fluid and brains of patients with Alzheimer\u2019s disease. Nihon Ronen Igakkai zasshi Jpn J Geriatr. 1998;35(4):273\u20137.","journal-title":"Nihon Ronen Igakkai zasshi Jpn J Geriatr."},{"issue":"3","key":"71_CR60","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0304-3940(01)01657-3","volume":"301","author":"N Schupf","year":"2001","unstructured":"Schupf N, Patel B, Silverman W, Zigman WB, Zhong N, Tycko B, et al. Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome. Neurosci Lett. 2001;301(3):199\u2013203.","journal-title":"Neurosci Lett"},{"issue":"3","key":"71_CR61","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0304-3940(03)00275-1","volume":"342","author":"PD Mehta","year":"2003","unstructured":"Mehta PD, Mehta SP, Fedor B, Patrick BA, Emmerling M, Dalton AJ. Plasma amyloid beta protein 1-42 levels are increased in old Down syndrome but not in young Down syndrome. Neurosci Lett. 2003;342(3):155\u20138.","journal-title":"Neurosci Lett."},{"issue":"7","key":"71_CR62","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/archneur.64.7.1007","volume":"64","author":"N Schupf","year":"2007","unstructured":"Schupf N, Patel B, Pang D, Zigman WB, Silverman W, Mehta PD, et al. Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome. Arch Neurol. 2007;64(7):1007\u201313.","journal-title":"Arch Neurol."},{"issue":"4","key":"71_CR63","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s12017-016-8413-y","volume":"18","author":"R Obeid","year":"2016","unstructured":"Obeid R, Hubner U, Bodis M, Geisel J. Plasma amyloid beta 1-42 and DNA methylation pattern predict accelerated aging in young subjects with Down syndrome. Neuromol Med. 2016;18(4):593\u2013601.","journal-title":"Neuromol Med."},{"key":"71_CR64","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jalz.2016.08.012","volume":"13","author":"ED Hamlett","year":"2016","unstructured":"Hamlett ED, Goetzl EJ, Ledreux A, Vasilevko V, Boger HA, LaRosa A, et al. Neuronal exosomes reveal Alzheimer\u2019s disease biomarkers in Down syndrome. Alzheimers Dement. 2016;13:541\u20139.","journal-title":"Alzheimers Dement."},{"issue":"9","key":"71_CR65","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/j.neurobiolaging.2011.08.007","volume":"33","author":"AM Coppus","year":"2012","unstructured":"Coppus AM, Schuur M, Vergeer J, Janssens AC, Oostra BA, Verbeek MM, et al. Plasma beta amyloid and the risk of Alzheimer\u2019s disease in Down syndrome. Neurobiol Aging. 2012;33(9):1988\u201394.","journal-title":"Neurobiol Aging."},{"issue":"18","key":"71_CR66","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1212\/WNL.0b013e3181fb448b","volume":"75","author":"N Schupf","year":"2010","unstructured":"Schupf N, Zigman WB, Tang MX, Pang D, Mayeux R, Mehta P, et al. Change in plasma Ass peptides and onset of dementia in adults with Down syndrome. Neurology. 2010;75(18):1639\u201344.","journal-title":"Neurology."},{"issue":"2","key":"71_CR67","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/gps.2321","volume":"25","author":"VP Prasher","year":"2010","unstructured":"Prasher VP, Sajith SG, Mehta P, Zigman WB, Schupf N. Plasma beta-amyloid and duration of Alzheimer\u2019s disease in adults with Down syndrome. Int J Geriatr Psychiatry. 2010;25(2):202\u20137.","journal-title":"Int J Geriatr Psychiatry."},{"issue":"2","key":"71_CR68","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.neulet.2008.12.030","volume":"451","author":"EL Jones","year":"2009","unstructured":"Jones EL, Hanney M, Francis PT, Ballard CG. Amyloid beta concentrations in older people with Down syndrome and dementia. Neurosci Lett. 2009;451(2):162\u20134.","journal-title":"Neurosci Lett."},{"issue":"3","key":"71_CR69","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3233\/JAD-2010-101335","volume":"23","author":"E Head","year":"2011","unstructured":"Head E, Doran E, Nistor M, Hill M, Schmitt FA, Haier RJ, et al. Plasma amyloid-beta as a function of age, level of intellectual disability, and presence of dementia in Down syndrome. J Alzheimer\u2019s Dis. 2011;23(3):399\u2013409.","journal-title":"J Alzheimer\u2019s Dis."},{"issue":"4","key":"71_CR70","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/WAD.0b013e3181aba61e","volume":"23","author":"Y Matsuoka","year":"2009","unstructured":"Matsuoka Y, Andrews HF, Becker AG, Gray AJ, Mehta PD, Sano MC, et al. The relationship of plasma Abeta levels to dementia in aging individuals with Down syndrome. Alzheimer Dis Assoc Disord. 2009;23(4):315\u20138.","journal-title":"Alzheimer Dis Assoc Disord."},{"key":"71_CR71","first-page":"316","volume":"8","author":"NC Lee","year":"2016","unstructured":"Lee NC, Yang SY, Chieh JJ, Huang PT, Chang LM, Chiu YN, et al. Blood beta-amyloid and tau in Down syndrome: a comparison with Alzheimer\u2019s disease. Front Aging Neurosci. 2016;8:316.","journal-title":"Front Aging Neurosci."},{"issue":"6","key":"71_CR72","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/1531-8249(199912)46:6<933::AID-ANA20>3.0.CO;2-4","volume":"46","author":"A Tamaoka","year":"1999","unstructured":"Tamaoka A, Sekijima Y, Matsuno S, Tokuda T, Shoji S, Ikeda SI. Amyloid beta protein species in cerebrospinal fluid and in brain from patients with Down\u2019s syndrome. Ann Neurol. 1999;46(6):933.","journal-title":"Ann Neurol."},{"issue":"2","key":"71_CR73","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s12017-014-8302-1","volume":"16","author":"E Portelius","year":"2014","unstructured":"Portelius E, Holtta M, Soininen H, Bjerke M, Zetterberg H, Westerlund A, et al. Altered cerebrospinal fluid levels of amyloid beta and amyloid precursor-like protein 1 peptides in Down\u2019s syndrome. Neuromol Med. 2014;16(2):510\u20136.","journal-title":"Neuromol Med."},{"issue":"2","key":"71_CR74","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000358800","volume":"14","author":"E Portelius","year":"2014","unstructured":"Portelius E, Soininen H, Andreasson U, Zetterberg H, Persson R, Karlsson G, et al. Exploring Alzheimer molecular pathology in Down\u2019s syndrome cerebrospinal fluid. Neurodegener Dis. 2014;14(2):98\u2013106.","journal-title":"Neurodegener Dis."},{"key":"71_CR75","doi-asserted-by":"crossref","first-page":"1600604","DOI":"10.1109\/TASC.2012.2229772","volume":"23","author":"SY Yang","year":"2013","unstructured":"Yang SY, Chieh JJ, Yang CC, Liao SH, Chen HH, Horng HE, et al. Clinic applications in assaying ultra-low-concentration bio-markers using HTS SQUID-based AC magnetosusceptometer. IEEE Trans Appl Supercond. 2013;23:1600604.","journal-title":"IEEE Trans Appl Supercond."},{"issue":"11","key":"71_CR76","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jalz.2016.05.001","volume":"12","author":"MF Iulita","year":"2016","unstructured":"Iulita MF, Ower A, Barone C, Pentz R, Gubert P, Romano C, et al. An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: relation to cognitive decline and longitudinal evaluation. Alzheimers Dement. 2016;12(11):1132\u201348.","journal-title":"Alzheimers Dement."},{"issue":"3","key":"71_CR77","doi-asserted-by":"crossref","first-page":"871","DOI":"10.3233\/JAD-140783","volume":"43","author":"AD Dekker","year":"2015","unstructured":"Dekker AD, Coppus AM, Vermeiren Y, Aerts T, van Duijn CM, Kremer BP, et al. Serum MHPG strongly predicts conversion to Alzheimer\u2019s disease in behaviorally characterized subjects with Down syndrome. J Alzheimer\u2019s Dis. 2015;43(3):871\u201391.","journal-title":"J Alzheimer\u2019s Dis."},{"issue":"2","key":"71_CR78","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/ajmg.b.32389","volume":"171B","author":"EC Jenkins","year":"2016","unstructured":"Jenkins EC, Ye L, Krinsky-McHale SJ, Zigman WB, Schupf N, Silverman WP. Telomere longitudinal shortening as a biomarker for dementia status of adults with Down syndrome. Am J Med Genet B. 2016;171B(2):169\u201374.","journal-title":"Am J Med Genet B."}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-017-0071-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T07:57:30Z","timestamp":1569916650000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40120-017-0071-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":78,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["71"],"URL":"https:\/\/doi.org\/10.1007\/s40120-017-0071-y","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}